Thrombosis formation on disrupted atherosclerotic plaque is the most common acuse of cardiovascular diseases, in the pathophysiology, increased platelet reactivity is a descriptor of the risk of cardiovascular events ...Thrombosis formation on disrupted atherosclerotic plaque is the most common acuse of cardiovascular diseases, in the pathophysiology, increased platelet reactivity is a descriptor of the risk of cardiovascular events in healthy persons and in patients with overt coronary artery disease. Regardless of the stimulus for activation platelet-platelet interation and thrombus formation is ultimately regulated through the GP Ⅱ b/Ⅲ a receptor展开更多
Platelet activation plays an important role in thrombosis. Platelet glycoprotein Ⅱ b/Ⅲ a （ GPⅡ b/Ⅲ a ） is the receptor of fibrinogen. Platelet cross-linking with fibrinogen through GP Ⅱ b/Ⅲ a is the process of...Platelet activation plays an important role in thrombosis. Platelet glycoprotein Ⅱ b/Ⅲ a （ GPⅡ b/Ⅲ a ） is the receptor of fibrinogen. Platelet cross-linking with fibrinogen through GP Ⅱ b/Ⅲ a is the process of thrombosis. Ca^2＋ is an important intracellular second messenger in platelet activation. It has been reported that GP Ⅱ b/Ⅲ a receptors were involved in the calcium influx of activated platelet, and GP Ⅱ b/Ⅲ a receptor had characteristics of calcium channel or an adjacent calcium channel.展开更多
To compare clinical outcomes and safety of eptifibatide or tirofiban in patients with acute coronary syndrome（ACS） undergoing percutaneous coronary intervention（PCI）. Methods：Thirty-six patients with ACS（unstabl...To compare clinical outcomes and safety of eptifibatide or tirofiban in patients with acute coronary syndrome（ACS） undergoing percutaneous coronary intervention（PCI）. Methods：Thirty-six patients with ACS（unstable angina/non-ST-segment elevation myocardial infarction, UA/NSTEMI） who underwent PCI were randomly divided into two groups to receive eptifibatide or tirofiban treatment. Eptifibatide or tirofiban was predominantly initiated in the catheter laboratory before the intervention. In-hospital and 30-day MACE outcomes; bleeding as well as platelet counting were investigated in those two groups. Results：No in-hospital and 30-day MACE event occurred in the two groups. The number of ischemia leads after treatment reduced compared to that before PCI in the two groups. There was improvement in the number of ischemia leads for 24 h after administration in the tirofiban group than those in eptifibatide group（4.21 ± 2.46 vs. 3.89 ± 3.31, P =0.03）. The two groups showed no incidence of massive bleeding. Minor bleeding rates were 16.7% and 22.2% in the two groups respectively. Conclusion：Eptifibatide as an adjunct to PCI may further decrease the incidence of ischemia event in patients with ACS and improve the safety, but its long-term efficacy and side effects need further observation.展开更多
This paper designed a detailed procedure for monogenic hypertension diagnosis by Whole Exome Sequencing(WES)and provided reliable precise medication guidance.Identification of mutated points provides the clinician val...This paper designed a detailed procedure for monogenic hypertension diagnosis by Whole Exome Sequencing(WES)and provided reliable precise medication guidance.Identification of mutated points provides the clinician valuable information for effective individualized therapeutic option.Therapeutic options that specifically restore the pathway disturbed by these point mutations can be selected to give a precise medicinal guidance.展开更多
Objective:To evaluate the efficacy and safety of tirofiban hydrochloride in the treatment of ischemic stroke with thrombolytic therapy.Method:Two hundred patients with acute ischemic stroke thrombolysis were randomly ...Objective:To evaluate the efficacy and safety of tirofiban hydrochloride in the treatment of ischemic stroke with thrombolytic therapy.Method:Two hundred patients with acute ischemic stroke thrombolysis were randomly divided into the experimental group and the control group.The experimental group was given tirofiban with the addition of rtpa in the control group and the therapeutic effects of the two groups were compared.Results:In comparison with the control group,the NIHSS improvement rate was 98%in the experimental group within 14 days.The platelet aggregation rate and efficacy in the experimental group were significantly reduced than the control group(P<0.01).The major adverse reaction in the two groups was hemorrhage with an incidence rate of 3%.Conclusion:Tirofiban hydrochloride is a highly effective and selective platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor,which is safe and effective in combination with heparin and aspirin.展开更多
目的探索在使用糖蛋白Ⅱb/Ⅲa受体拮抗剂(GPI)时替格瑞洛对比氯吡格雷在中国急性冠状动脉综合征(ACS)患者中的有效性和安全性。方法分析中国心血管疾病医疗质量改善-ACS(Improving Care for Cardiovascular Disease in China-ACS,CCC-A...目的探索在使用糖蛋白Ⅱb/Ⅲa受体拮抗剂(GPI)时替格瑞洛对比氯吡格雷在中国急性冠状动脉综合征(ACS)患者中的有效性和安全性。方法分析中国心血管疾病医疗质量改善-ACS(Improving Care for Cardiovascular Disease in China-ACS,CCC-ACS)项目中使用GPI的ACS患者数据。根据使用替格瑞洛或氯吡格雷分组,通过多因素logistic分析和倾向性评分匹配(PSM)对比分析使用GPI时替格瑞洛与氯吡格雷对ACS患者住院期间发生主要不良心血管事件(MACE)和出血事件的风险。结果2014年11月1日至2017年6月1日CCC-ACS项目从全国150家三级医院共收集63641例ACS患者。多因素logistic回归分析显示,在使用GPI时替格瑞洛较氯吡格雷在减少MACE的发生率上差异无统计学意义(OR=0.881,95%CI 0.599~1.296;P=0.521),但替格瑞洛组主要出血率较高(OR=1.401,95%CI 1.075~1.852;P=0.013)。PSM后结果提示,在使用GPI时替格瑞洛组和氯吡格雷组在MACE发生上差异无统计学意义(OR=0.919,95%CI 0.613~1.376;P=0.681);但替格瑞洛组发生主要出血率高于氯吡格雷组(OR=1.559,95%CI 1.130~2.150;P=0.007)。结论在中国人群中,常规使用GPI时替格瑞洛较氯吡格雷没有减少ACS患者MACE的发生风险,但增加了出血风险。展开更多
目的观察不同血管分型的进展性缺血性脑卒中(PIS)的基线特征及应用替罗非班的临床效果。方法回顾性选取2020年3月—2022年3月湘潭市中心医院收治的PIS患者89例,根据治疗方法不同分为观察组42例和对照组47例。对照组患者予以常规治疗及...目的观察不同血管分型的进展性缺血性脑卒中(PIS)的基线特征及应用替罗非班的临床效果。方法回顾性选取2020年3月—2022年3月湘潭市中心医院收治的PIS患者89例,根据治疗方法不同分为观察组42例和对照组47例。对照组患者予以常规治疗及阿司匹林100 mg联合氢氯吡格雷75 mg抗血小板聚集,观察组患者在对照组基础上加用替罗非班治疗,根据责任血管(小动脉闭塞型和大动脉粥样硬化型)进一步亚组分析,比较各组NIHSS评分、住院时间,随访90 d,比较各组mRS评分、焦虑、抑郁及胃肠道出血发生率。结果观察组与对照组及各亚组基线特征、入院时NIHSS评分、加重时NIHSS评分比较差异均无统计学意义(P>0.05);观察组治疗7 d后NIHSS评分低于对照组,ΔNIHSS评分及随访90 d mRS评分良好率高于对照组,住院时间短于对照组(P<0.05)。根据责任血管分型的亚组分析显示,在小动脉闭塞亚组中,观察亚组加重7 d后的NIHSS评分低于对照亚组,ΔNIHSS评分及随访90 d mRS评分良好率高于对照亚组,住院时间短于对照亚组(P<0.05);而在大动脉粥样硬化亚组中,2亚组患者基线特征、入院时NIHSS评分、加重时NIHSS评分、治疗7 d后NIHSS评分、ΔNIHSS评分、住院时间及随访90 d mRS评分良好率比较差异均无统计学意义(P>0.05)。随访90 d,观察组与对照组及各亚组焦虑、抑郁、胃肠道出血发生率比较差异均无统计学意义(P>0.05)。结论与口服抗血小板药物比较,替罗非班对不同责任血管导致的PIS疗效可能存在差异,替罗非班可显著改善小动脉闭塞型PIS的神经功能缺损,疗效确切,且安全性高,值得推广应用。展开更多
文摘Thrombosis formation on disrupted atherosclerotic plaque is the most common acuse of cardiovascular diseases, in the pathophysiology, increased platelet reactivity is a descriptor of the risk of cardiovascular events in healthy persons and in patients with overt coronary artery disease. Regardless of the stimulus for activation platelet-platelet interation and thrombus formation is ultimately regulated through the GP Ⅱ b/Ⅲ a receptor
文摘Platelet activation plays an important role in thrombosis. Platelet glycoprotein Ⅱ b/Ⅲ a （ GPⅡ b/Ⅲ a ） is the receptor of fibrinogen. Platelet cross-linking with fibrinogen through GP Ⅱ b/Ⅲ a is the process of thrombosis. Ca^2＋ is an important intracellular second messenger in platelet activation. It has been reported that GP Ⅱ b/Ⅲ a receptors were involved in the calcium influx of activated platelet, and GP Ⅱ b/Ⅲ a receptor had characteristics of calcium channel or an adjacent calcium channel.
基金supported by a grant from ShenZhen Hybio Engineering Co.,Ltd.
文摘To compare clinical outcomes and safety of eptifibatide or tirofiban in patients with acute coronary syndrome（ACS） undergoing percutaneous coronary intervention（PCI）. Methods：Thirty-six patients with ACS（unstable angina/non-ST-segment elevation myocardial infarction, UA/NSTEMI） who underwent PCI were randomly divided into two groups to receive eptifibatide or tirofiban treatment. Eptifibatide or tirofiban was predominantly initiated in the catheter laboratory before the intervention. In-hospital and 30-day MACE outcomes; bleeding as well as platelet counting were investigated in those two groups. Results：No in-hospital and 30-day MACE event occurred in the two groups. The number of ischemia leads after treatment reduced compared to that before PCI in the two groups. There was improvement in the number of ischemia leads for 24 h after administration in the tirofiban group than those in eptifibatide group（4.21 ± 2.46 vs. 3.89 ± 3.31, P =0.03）. The two groups showed no incidence of massive bleeding. Minor bleeding rates were 16.7% and 22.2% in the two groups respectively. Conclusion：Eptifibatide as an adjunct to PCI may further decrease the incidence of ischemia event in patients with ACS and improve the safety, but its long-term efficacy and side effects need further observation.
文摘This paper designed a detailed procedure for monogenic hypertension diagnosis by Whole Exome Sequencing(WES)and provided reliable precise medication guidance.Identification of mutated points provides the clinician valuable information for effective individualized therapeutic option.Therapeutic options that specifically restore the pathway disturbed by these point mutations can be selected to give a precise medicinal guidance.
文摘Objective:To evaluate the efficacy and safety of tirofiban hydrochloride in the treatment of ischemic stroke with thrombolytic therapy.Method:Two hundred patients with acute ischemic stroke thrombolysis were randomly divided into the experimental group and the control group.The experimental group was given tirofiban with the addition of rtpa in the control group and the therapeutic effects of the two groups were compared.Results:In comparison with the control group,the NIHSS improvement rate was 98%in the experimental group within 14 days.The platelet aggregation rate and efficacy in the experimental group were significantly reduced than the control group(P<0.01).The major adverse reaction in the two groups was hemorrhage with an incidence rate of 3%.Conclusion:Tirofiban hydrochloride is a highly effective and selective platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor,which is safe and effective in combination with heparin and aspirin.
文摘目的探索在使用糖蛋白Ⅱb/Ⅲa受体拮抗剂(GPI)时替格瑞洛对比氯吡格雷在中国急性冠状动脉综合征(ACS)患者中的有效性和安全性。方法分析中国心血管疾病医疗质量改善-ACS(Improving Care for Cardiovascular Disease in China-ACS,CCC-ACS)项目中使用GPI的ACS患者数据。根据使用替格瑞洛或氯吡格雷分组,通过多因素logistic分析和倾向性评分匹配(PSM)对比分析使用GPI时替格瑞洛与氯吡格雷对ACS患者住院期间发生主要不良心血管事件(MACE)和出血事件的风险。结果2014年11月1日至2017年6月1日CCC-ACS项目从全国150家三级医院共收集63641例ACS患者。多因素logistic回归分析显示,在使用GPI时替格瑞洛较氯吡格雷在减少MACE的发生率上差异无统计学意义(OR=0.881,95%CI 0.599~1.296;P=0.521),但替格瑞洛组主要出血率较高(OR=1.401,95%CI 1.075~1.852;P=0.013)。PSM后结果提示,在使用GPI时替格瑞洛组和氯吡格雷组在MACE发生上差异无统计学意义(OR=0.919,95%CI 0.613~1.376;P=0.681);但替格瑞洛组发生主要出血率高于氯吡格雷组(OR=1.559,95%CI 1.130~2.150;P=0.007)。结论在中国人群中,常规使用GPI时替格瑞洛较氯吡格雷没有减少ACS患者MACE的发生风险,但增加了出血风险。
文摘目的观察不同血管分型的进展性缺血性脑卒中(PIS)的基线特征及应用替罗非班的临床效果。方法回顾性选取2020年3月—2022年3月湘潭市中心医院收治的PIS患者89例,根据治疗方法不同分为观察组42例和对照组47例。对照组患者予以常规治疗及阿司匹林100 mg联合氢氯吡格雷75 mg抗血小板聚集,观察组患者在对照组基础上加用替罗非班治疗,根据责任血管(小动脉闭塞型和大动脉粥样硬化型)进一步亚组分析,比较各组NIHSS评分、住院时间,随访90 d,比较各组mRS评分、焦虑、抑郁及胃肠道出血发生率。结果观察组与对照组及各亚组基线特征、入院时NIHSS评分、加重时NIHSS评分比较差异均无统计学意义(P>0.05);观察组治疗7 d后NIHSS评分低于对照组,ΔNIHSS评分及随访90 d mRS评分良好率高于对照组,住院时间短于对照组(P<0.05)。根据责任血管分型的亚组分析显示,在小动脉闭塞亚组中,观察亚组加重7 d后的NIHSS评分低于对照亚组,ΔNIHSS评分及随访90 d mRS评分良好率高于对照亚组,住院时间短于对照亚组(P<0.05);而在大动脉粥样硬化亚组中,2亚组患者基线特征、入院时NIHSS评分、加重时NIHSS评分、治疗7 d后NIHSS评分、ΔNIHSS评分、住院时间及随访90 d mRS评分良好率比较差异均无统计学意义(P>0.05)。随访90 d,观察组与对照组及各亚组焦虑、抑郁、胃肠道出血发生率比较差异均无统计学意义(P>0.05)。结论与口服抗血小板药物比较,替罗非班对不同责任血管导致的PIS疗效可能存在差异,替罗非班可显著改善小动脉闭塞型PIS的神经功能缺损,疗效确切,且安全性高,值得推广应用。
